GlassScriptPhysician profile
Natalie M Lipscomb
NPI 1740786656
$7,306.62
in general payments reported to CMS, 2019-2025
33 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $626 · 2022: $1,518 · 2023: $2,095 · 2024: $1,936 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,162.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,238.58 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,174.44 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $832.59 | 2021-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $736.17 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $475.77 | 2022-2025 | |
| Lilly USA, LLC | $402.43 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $397.34 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.62 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Shield Therapeutics INC | $199.11 | 2023-2024 | Accrufer |
| Janssen Pharmaceuticals, INC | $171.96 | 2022-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $161.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $130.78 | 2022-2025 | |
| Astellas Pharma US INC | $116.23 | 2023-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $104.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $103.02 | 2021-2024 | Trintellix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $89.05 | 2022-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $82.06 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.27 | 2024-2025 | Caplyta |
| Corium, LLC | $58.91 | 2023-2024 | Adlarity, Azstarys |
| Merck Sharp & Dohme LLC | $54.35 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Mylan Specialty L.P. | $52.09 | 2022-2023 | Yupelri |
| Axsome Therapeutics, INC. | $41.39 | 2024 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $39.34 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $36.07 | 2022 | |
| Xeris Pharmaceuticals, INC. | $30.24 | 2021-2023 | Keveyis |
| Inspire Medical Systems, INC. | $29.35 | 2024 | Inspire |
| Sumitomo Pharma America, INC. | $24.06 | 2024 | Gemtesa |
| Biogen, INC. | $22.24 | 2023 | Skyclarys |
| Agios Pharmaceuticals, INC. | $22.04 | 2024 | Pyrukynd |
| Philips North America LLC | $17.91 | 2024 | (Ck6) Holter |
| E.R. Squibb & Sons, L.L.C. | $16.93 | 2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $14.74 | 2023 | Quviviq |
| Boston Scientific Corporation | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Lipscomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.